Alembic
Touching Lives over 100 years

Date: 6th August, 2021

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai

Dear Sir,

Sub: Outcome of Board Meeting

With reference to the captioned subject, the exchange is hereby informed that the Board of Directors of Alembic Limited at its meeting held today has inter alia approved the Unaudited Financial Results of the Company for the quarter ended on 30th June, 2021.

We enclose herewith the following:

1) Consolidated Unaudited Financial Results of the Company for the quarter ended on 30th June, 2021.
2) Standalone Unaudited Financial Results of the Company for the quarter ended on 30th June, 2021.
3) Limited Review Report by Statutory Auditors on Consolidated as well as on Standalone Unaudited Financial Results.

The time of commencement of the Board Meeting was 2:30 p.m. and the time of conclusion was 3:50 p.m.

We request you to kindly take the same on your record.

Thanking you.

Yours faithfully,
For Alembic Limited

ALEMBIC LIMITED Vadodara

Drigesh Mittal
Company Secretary

Encl.: A/a

ALEMBIC LIMITED
CIN:L26100GJ1907PLC000033
Regd.Office: Alembic Road, Vadodara 390 003
Ph:0265 2280550
www.alembiclimited.com Email:alembic.investors@alembic.co.in

Statement of Consolidated Unaudited Financial Results for the Quarter ended 30th June, 2021

Rs. in Lakhs

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Unaudited)	31.03.2021 (Audited)
1	**Revenue from Operations**	**2,082**	2,889	1,339	7,352
2	**Other Income**	**196**	177	282	1,027
3	**Total Income**	**2,278**	3,066	1,621	8,379
4	**Expenses**				
	Cost of Materials Consumed	**234**	405	253	1,177
	Cost of Construction	**248**	1,094	0	1,286
	Changes in Inventories of Finished Goods and WIP	**304**	(239)	72	(239)
	Employee Benefit Expenses	**547**	501	620	2,260
	Finance Costs	**10**	9	9	36
	Depreciation and amortisation expense	**113**	103	93	394
	Other Expenses	**341**	733	320	1,761
	Total Expenses	**1,797**	2,607	1,367	6,675
5	**Profit Before Tax**	**481**	459	254	1,704
6	**Tax Expenses**				
	Current Tax	**88**	93	12	290
	Deferred Tax	**8**	7	31	35
	Short / (Excess) Provision of earlier years	**-**	(6)	-	(6)
7	**Net Profit after tax for the Period**	**384**	364	211	1,384
8	**Share of Associate's Profit**	**4,522**	6,830	8,641	32,900
9	**Net Profit after tax and Share of Associate's Profit**	**4,906**	7,194	8,852	34,284
10	Other Comprehensive Income				
	A (i) Items that will not be reclassified to Profit or Loss	**(5,548)**	27,164	3,558	38,992
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss	**650**	(3,124)	(390)	(4,452)
	B (i) Items that will be reclassified to Profit or Loss	**53**	4	(8)	(75)
11	Total Comprehensive Income/(Loss) for the Period	**62**	31,238	12,011	68,749
12	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	**5,135.64**	5,135.64	5,135.64	5,135.64
13	Other Equity (excluding Revaluation Reserve)				1,80,277
14	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	**1.91**	2.80	3.45	13.35

CNK & ASSOCIATES LLP VADODARA CHARTERED ACCOUNTANTS

ALEMBIC LIMITED Vadodara

Alembic Limited

Segment wise Consolidated Revenue and Results — **Rs. In Lakhs**

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Unaudited)	31.03.2021 (Audited)
1	**Segment Revenue**				
	Revenue from Operations				
	a. Active Pharmaceutical Ingredients Business	**1,069**	716	727	2,849
	b. Real Estate Business	**1,013**	2,173	612	4,502
	Total Income from Operations (Net)	**2,082**	2,889	1,339	7,352
2	**Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)**				
	a. Active Pharmaceutical Ingredients Business	**141**	(163)	(52)	(128)
	b. Real Estate Business	**277**	571	100	1,312
	Total	**418**	408	48	1,184
	Unallocable Income and Expenditure				
	(i) Interest Expense	**(10)**	(9)	(9)	(36)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	**69**	(89)	151	115
	(iii) Other Income / (Expense)	**4**	150	63	442
	Total Profit Before Tax	**481**	459	254	1,704
3	**Segment Assets**				
	a. Active Pharmaceutical Ingredients Business	**15,115**	15,445	15,012	15,445
	b. Real Estate Business	**22,416**	21,494	13,798	21,494
	c. Unallocated	**2,02,840**	2,03,958	1,30,787	2,03,958
	Total	**2,40,370**	2,40,896	1,59,597	2,40,896
4	**Segment Liabilities**				
	a. Active Pharmaceutical Ingredients Business	**1,896**	1,712	1,653	1,712
	b. Real Estate Business	**4,661**	4,819	3,504	4,819
	c. Unallocated	**4,048**	4,663	624	4,663
	Total	**10,605**	11,193	5,781	11,193

Notes:

1 The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.

2 During the quarter ended 30th June 2021, due to resurgence of Covid-19, the Real Estate segment was adversely impacted with slow-down in construction activities, new residential bookings and rental activities. The API segment, being a part of essential services is largely unaffected.
The Company's management has made an internal assessment and believes that the impact is likely to be short term in nature and does not foresee any medium to long term risk in company's ability to continue as a going concern.

3 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Limited

ALEMBIC LIMITED Vadodara

Chirayu Amin
Chairman

Place : London
Date : 6th August, 2021

CNK & ASSOCIATES LLP VADODARA CHARTERED ACCOUNTANTS

ALEMBIC LIMITED
CIN:L26100GJ1907PLC000033
Regd.Office: Alembic Road, Vadodara 390 003
Ph:0265 2280550
www.alembiclimited.com Email:alembic.investors@alembic.co.in

Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June, 2021

Rs. in Lakhs

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Unaudited)	31.03.2021 (Audited)
1	**Revenue from Operations**	**2,039**	2,854	1,310	7,230
2	**Other Income**	**196**	172	281	997
3	**Total Income**	**2,235**	3,026	1,591	8,227
4	**Expenses**				
	Cost of Materials Consumed	**234**	405	253	1,177
	Cost of Construction	**248**	1,094	0	1,286
	Changes in Inventories of Finished Goods and WIP	**304**	(239)	72	(239)
	Employee Benefit Expenses	**547**	501	620	2,260
	Finance Costs	**7**	7	6	27
	Depreciation and amortisation expense	**104**	100	93	391
	Other Expenses	**319**	705	296	1,673
	Total Expenses	**1,764**	2,573	1,341	6,575
5	**Profit Before Tax**	**471**	453	250	1,652
6	**Tax Expenses**				
	Current Tax	**88**	93	12	290
	Deferred Tax	**8**	3	31	31
	Short / (Excess) Provision of earlier years	**-**	(6)	-	(6)
7	**Net Profit after tax for the Period**	**375**	363	207	1,336
8	Other Comprehensive Income				
	(i) Items that will not be reclassified to Profit or Loss	**(5,392)**	27,003	3,751	39,035
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss	**624**	(3,096)	(424)	(4,458)
9	Total Comprehensive Income/(Loss) for the Period	**(4,394)**	24,270	3,534	35,913
10	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	**5,135.64**	5,135.64	5,135.64	5,135.64
11	Other Equity (excluding Revaluation Reserve)				33,256
12	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	**0.15**	0.14	0.08	0.52

C.N.K. & ASSOCIATES LLP VADODARA CHARTERED ACCOUNTANTS

ALEMBIC LIMITED Vadodara

Alembic Limited

Segment wise Standalone Revenue and Results

Rs. In Lakhs

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Unaudited)	31.03.2021 (Audited)
1	**Segment Revenue**				
	Revenue from Operations				
	a. Active Pharmaceutical Ingredients Business	1,069	716	727	2,849
	b. Real Estate Business	969	2,138	582	4,381
	Total Income from Operations (Net)	2,039	2,854	1,310	7,230
2	**Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)**				
	a. Active Pharmaceutical Ingredients Business	141	(163)	(52)	(128)
	b. Real Estate Business	264	562	93	1,250
	Total	406	399	42	1,122
	Unallocable Income and Expenditure				
	(i) Interest Expense	(7)	(7)	(6)	(27)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	69	(89)	151	115
	(iii) Other Income / (Expense)	4	150	63	442
	Total Profit Before Tax	471	453	250	1,652
3	**Segment Assets**				
	a. Active Pharmaceutical Ingredients Business	15,115	15,445	15,012	15,445
	b. Real Estate Business	21,710	20,284	13,707	20,284
	c. Unallocated	51,836	57,917	28,775	57,917
	Total	88,661	93,645	57,494	93,645
4	**Segment Liabilities**				
	a. Active Pharmaceutical Ingredients Business	1,896	1,712	1,653	1,712
	b. Real Estate Business	4,434	4,594	3,372	4,594
	c. Unallocated	4,043	4,658	624	4,658
	Total	10,373	10,963	5,649	10,963

Notes:

1 The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.

2 During the quarter ended 30st June 2021, due to resurgence of Covid-19, the Real Estate segment was adversely impacted with slow-down in construction activities, new residential bookings and rental activities. The API segment, being a part of essential services is largely unaffected.

The Company's management has made an internal assessment and believes that the impact is likely to be short term in nature and does not foresee any medium to long term risk in company's ability to continue as a going concern.

3 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Limited

ALEMBIC LIMITED Vadodara

Chirayu Amin
Chairman

Place : London
Date : 6th August, 2021

CNK & ASSOCIATES LLP VADODARA CHARTERED ACCOUNTANTS

CNK & Associates LLP
Chartered Accountants

C - 201 - 202, Shree Siddhi Vinayak Complex, Opp. Alkapuri Side Railway Station, Faramji Road, Alkapuri, Vadodara - 390 005.
Ph. : +91-265-2343483, 2354359
Email : alok@cnkindia.com

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of **Alembic Limited** ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30th June, 2021 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable

4. The statement includes results of the following entities:
   i. Alembic City Limited (Subsidiary)

   ii. Alembic Pharmaceuticals Limited (Associate)

CNK & ASSOCIATES LLP * VADODARA * CHARTERED ACCOUNTANTS

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose financial results reflect total revenue of Rs. 165.81 lakhs, total net loss after tax of Rs. 27.08 Lakhs and total comprehensive loss of Rs. 27.14 Lakhs for the quarter ended 30th June, 2021. The unaudited consolidated financial results also include the Group's share of net profit after tax of Rs. 4,521.99 Lakhs and total comprehensive income of Rs. 4,446.43 lakhs quarter ended 30th June, 2021, as considered in the statement, in respect of an associate. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the unaudited consolidated quarterly financial results is not modified with respect of the above matter.

For **CNK & Associates LLP**
Chartered Accountants
Firm Registration No. 101961W/W-100036

CNK & ASSOCIATES LLP VADODARA CHARTERED ACCOUNTANTS

Alok Shah
Partner
Membership No. 042005
Place : Vadodara
Date : 06th August, 2021
UDIN : 21042005AAAAMB9451

CNK & Associates LLP
Chartered Accountants

C - 201 - 202, Shree Siddhi Vinayak Complex, Opp. Alkapuri Side Railway Station,
Faramji Road, Alkapuri, Vadodara - 390 005.
Ph. : +91-265-2343483, 2354359
Email : alok@cnkindia.com

Independent Auditor's Review Report on Unaudited Standalone Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of **Alembic Limited** ("the Company") for the quarter ended 30th June, 2021 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the

CNK & ASSOCIATES LLP VADODARA CHARTERED ACCOUNTANTS

Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For **CNK & Associates LLP**
Chartered Accountants
Firm Registration No. 101961W/W-100036

Alok Shah
Partner
Membership No. 042005
Place : Vadodara
Date : 06th August, 2021
UDIN : 21042005AAAAMA3254

CNK & ASSOCIATES LLP
VADODARA
CHARTERED ACCOUNTANTS